A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly

OBJECTIVE: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. DESIGN: Twenty-six patients with active acromegaly (IGF-I >130%...

Descripción completa

Detalles Bibliográficos
Autores principales: Trainer, Peter J, Newell-Price, John D C, Ayuk, John, Aylwin, Simon J B, Rees, Aled, Drake, William, Chanson, Philippe, Brue, Thierry, Webb, Susan M, Fajardo, Carmen, Aller, Javier, McCormack, Ann I, Torpy, David J, Tachas, George, Atley, Lynne, Ryder, David, Bidlingmaier, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063983/
https://www.ncbi.nlm.nih.gov/pubmed/29789410
http://dx.doi.org/10.1530/EJE-18-0138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063983/
https://www.ncbi.nlm.nih.gov/pubmed/29789410
http://dx.doi.org/10.1530/EJE-18-0138

Ejemplares similares